



IPO INSIGHTS

CONCORD BIOTECH

Biotech for Mankind...

Concord Biotech Limited

Issue Dates - Opens:04-08-2023 | Closes: 08-08-2023

IPO Note	<ol style="list-style-type: none"> Concord Biotech Limited is an India-based R&D-driven biopharma company. The Company is a manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share.
Rating	★★★★ (Good)

IPO SNAPSHOT

Issue Size	₹ 1551 Crores
Issue Type	Book Built IPO
Fresh Issue	-
Offer for Sale	₹1551 Crores
Face Value Per Share	₹ 1
Price Band Per Share	₹705 to ₹741
Minimum Lot Size	20 shares
Listing On	BSE, NSE

Registrar to the Issue

Link Intime India Private Ltd

IPO SNAPSHOT – Concord Biotech Limited

About the Company	<ul style="list-style-type: none"> ▪ Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company. ▪ The company manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. ▪ They are supplying their products to over 70 countries including the USA, India, Europe, and Japan. ▪ The company is ranked among the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022. ▪ The Company also has a robust pipeline of products under development. 																														
Competitive Strengths	<ul style="list-style-type: none"> ▪ The company has a strong presence throughout the complex fermentation process. ▪ They are global leader in immunosuppressant APIs and offer a wide range of complex fermentation-based APIs for various medical fields. ▪ Their manufacturing facilities are well-established and scalable, maintaining consistent regulatory compliance. Additionally, they possess strong R&D capabilities. 																														
Financials (₹ in Crore)	<table border="1"> <thead> <tr> <th>Particulars</th> <th>31-3-2021</th> <th>31-3-2022</th> <th>31-3-2023</th> <th>Y-o-Y</th> </tr> </thead> <tbody> <tr> <td>Revenue from Operations</td> <td>616.94</td> <td>712.93</td> <td>853.16</td> <td>20%</td> </tr> <tr> <td>EBITDA</td> <td>327.55</td> <td>273.27</td> <td>343.28</td> <td>26%</td> </tr> <tr> <td>EBITDA Margin</td> <td>53.1%</td> <td>38.3%</td> <td>40.2%</td> <td></td> </tr> <tr> <td>Profit After Tax</td> <td>234.88</td> <td>174.82</td> <td>240.08</td> <td>37%</td> </tr> <tr> <td>Profit After Tax Margin</td> <td>38.1%</td> <td>24.5%</td> <td>28.1%</td> <td></td> </tr> </tbody> </table>	Particulars	31-3-2021	31-3-2022	31-3-2023	Y-o-Y	Revenue from Operations	616.94	712.93	853.16	20%	EBITDA	327.55	273.27	343.28	26%	EBITDA Margin	53.1%	38.3%	40.2%		Profit After Tax	234.88	174.82	240.08	37%	Profit After Tax Margin	38.1%	24.5%	28.1%	
Particulars	31-3-2021	31-3-2022	31-3-2023	Y-o-Y																											
Revenue from Operations	616.94	712.93	853.16	20%																											
EBITDA	327.55	273.27	343.28	26%																											
EBITDA Margin	53.1%	38.3%	40.2%																												
Profit After Tax	234.88	174.82	240.08	37%																											
Profit After Tax Margin	38.1%	24.5%	28.1%																												
Valuation	<ul style="list-style-type: none"> ▪ Attributing Annualized FY23 Earnings asking P/E = 32.28 																														
Peers	<table border="1"> <thead> <tr> <th>Company Name</th> <th>P/E ratio</th> </tr> </thead> <tbody> <tr> <td>Divi's Laboratories Limited</td> <td>54.15</td> </tr> <tr> <td>Suven Pharmaceuticals Limited</td> <td>30.08</td> </tr> <tr> <td>Laurus Labs Limited</td> <td>23.70</td> </tr> </tbody> </table>	Company Name	P/E ratio	Divi's Laboratories Limited	54.15	Suven Pharmaceuticals Limited	30.08	Laurus Labs Limited	23.70																						
Company Name	P/E ratio																														
Divi's Laboratories Limited	54.15																														
Suven Pharmaceuticals Limited	30.08																														
Laurus Labs Limited	23.70																														
Promoter	<ul style="list-style-type: none"> ▪ Sudhir Vaid ▪ Ankur Vaid 																														
Objects of the issue	<ul style="list-style-type: none"> ▪ Issue Expenses ▪ Listing gains 																														

DISCLAIMER

The information provided by or in this newsletter is generally from the press reports, electronic media, research websites and other media. It also includes information from interviews conducted, analysis, views expressed by our research team. Investors should not rely solely on the information contained in this publication and must make their own investment decision based on their specific objectives and financial positions and using such independent advisor as they believe necessary. The material and the information provided herein are not and should not be construed as an advice to buy or sell any of the securities named in this newsletter. SIHL may or may not hold positions in any of the securities named in this newsletter as a part of its business. Past performance is not necessarily an indication of future performance. SIHL does not assure for accuracy and correctness of information of reports in this newsletter.

